Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (2016 - 2025)

Perspective Therapeutics' Shares Outstanding history spans 14 years, with the latest figure at $74.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 10.03% year-over-year to $74.3 million; the TTM value through Sep 2025 reached $74.3 million, up 10.03%, while the annual FY2024 figure was $70.7 million, 150.78% up from the prior year.
  • Shares Outstanding for Q3 2025 was $74.3 million at Perspective Therapeutics, roughly flat from $74.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $280.6 million in Q3 2023 and bottomed at $14.2 million in Q4 2022.
  • The 5-year median for Shares Outstanding is $74.3 million (2025), against an average of $111.1 million.
  • The largest annual shift saw Shares Outstanding soared 239407.77% in 2021 before it plummeted 89.99% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $142.0 million in 2021, then tumbled by 89.99% to $14.2 million in 2022, then skyrocketed by 98.3% to $28.2 million in 2023, then skyrocketed by 150.78% to $70.7 million in 2024, then increased by 5.19% to $74.3 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Shares Outstanding are $74.3 million (Q3 2025), $74.3 million (Q2 2025), and $74.1 million (Q1 2025).